Cleveland Clinic Abu Dhabi, in a partnership with AI biotech firm Owkin, has launched what it describes as the world’s first ‘clinical AI scientist’. The platform, named Aila, is designed to analyze complex clinical data and generate medical insights in real time, aiming to shorten the time for clinical decision-making from days or weeks to mere moments.
Quick Facts
- Launch of Aila, the ‘world’s first clinical AI scientist’
- Initial deployment focuses on prostate cancer diagnostics
- Developed in partnership with AI biotech company Owkin
- Provides real-time analysis of fragmented patient data
From Days to Real-Time: Aila’s Mission to Unify Clinical Data
Aila is built to address a fundamental challenge in healthcare: the time it takes to gather and interpret data from disparate sources. The platform transforms fragmented clinical information—including electronic health records, physician notes, pathology reports, and medical imaging—into a single, queryable knowledge layer available directly at the point of care. Its primary goal is to give clinicians immediate access to deep insights derived from a patient’s complete data profile precisely when critical decisions are being made.
This integration is key to Aila’s value. By connecting data that traditionally exists in separate silos across a patient’s medical history, the platform aims to have a significant impact on clinical workflows, patient experience, and ultimately, health outcomes.
How Aila Works: An Agentic AI Collaborator
Built on Owkin’s agentic K Pro biology platform, Aila functions more like an active scientific collaborator than a passive analytical tool. Physicians can use a secure, natural-language interface to query vast amounts of clinical data and receive answers that would have previously required days of manual analysis.
The system is designed to continuously learn and improve. By being trained natively on patient-level multimodal data and receiving real biological feedback, Aila refines its capabilities through clinical use rather than depending on periodic manual retraining. The platform is engineered to scale across other medical specialities and incorporate more complex data types over time, including multiomics and genomic data, to support large-scale precision medicine initiatives.
Abu Dhabi’s AI Ecosystem Powers Global Launch
The deployment is supported by the UAE’s advanced AI-enabled infrastructure, positioning Abu Dhabi’s healthcare ecosystem as the ideal launchpad for a globally significant clinical AI. The status of Cleveland Clinic Abu Dhabi, ranked as the top hospital in the UAE, lends both credibility and scale to the initial rollout of the technology.
This collaboration is part of Owkin’s larger vision to build thousands of AI scientists that work continuously to accelerate medical breakthroughs. The company’s model relies on exclusive partnerships with world-class hospitals to access unique longitudinal patient datasets and automated lab infrastructure.
About Cleveland Clinic Abu Dhabi
A joint venture between the US-based Cleveland Clinic and Abu Dhabi sovereign investor Mubadala Investment Company, Cleveland Clinic Abu Dhabi is a multidisciplinary hospital. The facility has a capacity of 490 beds and houses more than 50 medical and surgical subspecialties, including institutes for cancer, neurology, and cardiac care. It has consistently been ranked as the top hospital in the UAE by Newsweek from 2022 to 2026.
Source: Middle East AI News
